<DOC>
	<DOCNO>NCT02040766</DOCNO>
	<brief_summary>This randomize , double-blind , double-dummy , placebo-controlled , parallel-group , 12-week study evaluate efficacy safety beclomethasone dipropionate ( 80 160 mcg/day ) administer via breath-actuated inhaler ( BAI ) metered-dose inhaler ( MDI ) pediatric patient 4 11 year age persistent asthma , compare placebo .</brief_summary>
	<brief_title>A Safety Efficacy Study Beclomethasone Dipropionate Delivered Via Breath-Actuated Inhaler ( BAI ) Metered-Dose Inhaler ( MDI ) Participants Ages 4-11 Years Old With Persistent Asthma</brief_title>
	<detailed_description />
	<mesh_term>Asthma</mesh_term>
	<mesh_term>Beclomethasone</mesh_term>
	<mesh_term>Albuterol</mesh_term>
	<criteria>Written inform consent Asthma diagnosis : The patient diagnosis asthma define National Institute Health ( NIH ) . The asthma diagnosis present minimum 3 month stable ( defined exacerbation change medication ) least 30 day screen visit Severity disease : The patient persistent asthma , force expiratory volume 1 second ( FEV1 ) 40 % 90 % value predict age , height , sex screen visit ( SV ) Current asthma therapy : The patient currently treat 1 following : 1 ) stable daily dosage inhale corticosteroid ( ICS ) range 88176 mcg/day fluticasone propionate ( equivalent ) minimum 4 week ( 28 day ) screen visit 2 ) stable daily dosage noncorticosteroid therapy 3 ) daily dose ICS plus longacting beta2agonist ( LABA ) ( dose less equivalent fluticasone propionate 100 mcg/salmeterol 50 mcg twice daily ) Reversibility disease : The patient demonstrate least 12 % reversibility FEV1 within 30 minute 24 inhalation albuterol/salbutamol hydrofluoroalkane ( HFA ) MDI ( 90 mcg exactuator ) equivalent screen visit retesting . Other criterion apply , please contact investigator information The patient history lifethreatening asthma , define protocol asthma episode require intubation and/or associate hypercapnia , respiratory arrest , hypoxic seizure . The patient pregnant lactating , plan become pregnant study period 30 day patient 's last studyrelated visit ( eligible patient , applicable ) . Any patient become pregnant study withdrawn study . The patient know hypersensitivity corticosteroid excipients study drug rescue medication formulation . The patient use tobacco product within past year ( eg , cigarette , cigar , chew tobacco , pipe tobacco , applicable ) . The patient asthma exacerbation require oral corticosteroid within 30 day screen visit , hospitalization asthma within 2 month screen visit . The patient historical current evidence clinically significant disease . Significant disease define disease medical judgment investigator would put safety patient risk participation could affect efficacy safety analysis disease/condition worsen study . Other criterion apply , please contact investigator information</criteria>
	<gender>All</gender>
	<minimum_age>4 Years</minimum_age>
	<maximum_age>11 Years</maximum_age>
	<verification_date>April 2016</verification_date>
	<keyword>asthma</keyword>
	<keyword>breath-actuated inhaler</keyword>
	<keyword>meter dose inhaler</keyword>
</DOC>